353,983 Shares in Emergent Biosolutions Inc. $EBS Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Emergent Biosolutions Inc. (NYSE:EBS) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 353,983 shares of the biopharmaceutical company’s stock, valued at approximately $2,966,000.

Several other large investors have also recently bought and sold shares of EBS. Torren Management LLC acquired a new stake in Emergent Biosolutions in the fourth quarter worth $37,000. CANADA LIFE ASSURANCE Co acquired a new position in shares of Emergent Biosolutions in the 4th quarter valued at $45,000. Legal & General Group Plc bought a new stake in shares of Emergent Biosolutions in the 2nd quarter valued at $31,000. Farther Finance Advisors LLC increased its position in shares of Emergent Biosolutions by 361.3% in the 4th quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 4,827 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Emergent Biosolutions during the 2nd quarter worth $53,000. Institutional investors own 78.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. JPMorgan Chase & Co. assumed coverage on Emergent Biosolutions in a research note on Friday, August 21st. They issued an “underweight” rating for the company. UBS Group reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. HC Wainwright cut their price objective on Emergent Biosolutions from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Weiss Ratings upgraded Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, August 21st. Finally, Benchmark reissued a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $10.00.

Insider Buying and Selling

In other Emergent Biosolutions news, SVP Paul Anthony Williams sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total value of $25,200.00. Following the sale, the senior vice president owned 159,098 shares in the company, valued at approximately $1,336,423.20. The trade was a 1.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.00% of the company’s stock.

Emergent Biosolutions Stock Performance

EBS opened at $5.92 on Friday. The company has a market capitalization of $303.52 million, a price-to-earnings ratio of -1.67 and a beta of 2.35. The business’s 50-day moving average price is $6.88 and its two-hundred day moving average price is $8.08. Emergent Biosolutions Inc. has a 1 year low of $4.36 and a 1 year high of $14.06. The company has a debt-to-equity ratio of 1.70, a current ratio of 5.42 and a quick ratio of 2.95.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.68. The company had revenue of $234.30 million during the quarter, compared to analysts’ expectations of $177.50 million. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%. Equities analysts expect that Emergent Biosolutions Inc. will post -4.61 EPS for the current fiscal year.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.